Skip to main content
SpringerLink
Log in

Pharmacological Cardioversion of Atrial Fibrillation: Which Drugs Are Preferred, Class IC or Class III?

  • Chapter
Cardiac Arrhythmias 2005

  • 659 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Singer DE, Albers GW, Dalen JE et al (2004) Antithrombotic therapy in atrial fibrillation. The Seventh ACCP Conference on antithrombotic and thrombolytic therapy. Chest 126:429S–456S

    Article  PubMed  CAS  Google Scholar 

  2. Borgeat A, Goy JJ, Maendly R et al (1986) Flecainide versus quinidine for conversion of atrial fibrillation to sinus rhythm. Am J Cardiol 58:496–498

    Article  PubMed  CAS  Google Scholar 

  3. Suttorp MJ, Kingma JH, Lie-A-Hauel et al (1989) Intravenous flecainide versus verapamil for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol 63:693–696

    Article  PubMed  CAS  Google Scholar 

  4. Suttorp MJ, Kingma JH, Jessuron EK et al (1990) The value of class IC antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol 16:1722–1727

    PubMed  CAS  Google Scholar 

  5. Bianconi L, Boccadamo R, Pappalardo A et al (1989) Effectiveness of intravenous propafenone for conversion of atrial fibrillation and flutter of recent onset. Am J Cardiol 64:335–338

    Article  PubMed  CAS  Google Scholar 

  6. Bertini G, Conti A, Fradella G et al (1990) Propafenone versus amiodarone in field treatment of primary atrial tachydysrhythmias. J Emerg Med 8:15–20

    Article  PubMed  CAS  Google Scholar 

  7. Neuss M, Buss J, Schlepper M et al (1983) Effects of flecainide on electrophysiological properties of accessory pathways in the Wolff-Parkinson-White syndrome. Eur Heart J 4:347–353

    PubMed  CAS  Google Scholar 

  8. Hellenstrand KJ, Nathan AW, Bexton RS et al (1984) Electrophysiologic effects of flecainide acetate on sinus node function anomalous, atrioventricular connections and pacemaker threshold. Am J Cardiol 53(Suppl B):30–38

    Article  Google Scholar 

  9. Breithardt G, Borggrefe M, Wiebringhaus E et al (1984) Effect of propafenone in the Wolff-Parkinson-White syndrome: electrophysiological findings and long-term follw-up. Am J Cardiol 54:29D–39D

    Article  PubMed  CAS  Google Scholar 

  10. Kim SS, Lae R, Ruffy R (1986) Treatment of paroxysmal supraventricular tachycardia with flecainide acetate. Am J Cardiol 58:80–85

    Article  PubMed  CAS  Google Scholar 

  11. Shen EN, Keung E, Huicke E et al (1986) Intravenous propafenone for termination of reentrant supraventricular tachycardia. A placebo-controlled, randomized, double-blind, cross-over study. Ann Intern Med 105:655–659

    PubMed  CAS  Google Scholar 

  12. Hammil SC, Mc Laran CJ, Wood DL et al (1987) Double blind study of intravenous propafenone for paroxysmal supraventricular re-entrant tachycardia. J Am Coll Cardiol 9:1364–1368

    Google Scholar 

  13. Ludmer PL, Mc Cowan NE, Antman EM et al (1987) Efficacy of propafenone in Wolff-Parkinson-White syndrome: electrophysiologic findings and long-term follow-up. J Am Coll Cardiol 9:1357–1363

    PubMed  CAS  Google Scholar 

  14. Dubuc M, Kus T, Campa MA et al (1989) Electrophysiologic effects of intravenous propafenone in Wolff-Parkinson-White syndrome. Am Heart J 117:370–376

    Article  PubMed  CAS  Google Scholar 

  15. Kappenberger LJ, Fromer MA, Shenasa M et al (1985) Evaluation of flecainide acetate in rapid atrial fibrillation complicating Wolff-Parkinson-White syndrome. Clin Cardiol 8:321–326

    Article  PubMed  CAS  Google Scholar 

  16. Manolis AS, Salen DN, Estes NAM et al (1989) Electrophysiologic effects, efficacy and tolerance of class IC antiarrhythmic agent in Wolff-Parkinson-White syndrome. Am J Cardiol 63:746–750

    Article  PubMed  CAS  Google Scholar 

  17. Vitale P, Stefano R, Auricchio A (1986) Possibile pericolosità dell’amiodarone per via endovenosa rapida nel corso di tachicardia da rientro in soggetti con Wolff-Parkinson-White. G It Cardiol 16:969–974

    CAS  Google Scholar 

  18. Capucci A, Lenzi T, Boriani G et al (1992) Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol 70:69–72

    Article  PubMed  CAS  Google Scholar 

  19. Capucci A, Boriani G, Rubino I et al (1994) A controlled study on oral propafenone versus digoxin plus quinidine in converting recent-onset atrial fibrillation to sinus rhythm. Int J Cardiol 43:305–313

    Article  PubMed  CAS  Google Scholar 

  20. Capucci A, Boriani G, Botto GL et al (1994) Conversion of recent-onset atrial fibrillation by a single oral loading dose of propafenone or flecainide. Am J Cardiol 74:503–505

    Article  PubMed  CAS  Google Scholar 

  21. Baldi N, Russo VA, Morrone V et al (1998) Home treatment of recent-onset atrial Fibrillation with a single oral dose of flecainide or propafenone: an efficacious, reproducible and safe procedure. G It Cardiol 29(Suppl 5):380–383

    Google Scholar 

  22. Alboni P, Botto GL, Baldi N et al (2004) Out patients treatment of recent-onset atrial fibrillation with the ‘pill in the pocket’ approach. N Engl J Med 351:2384–2391

    Article  PubMed  CAS  Google Scholar 

  23. Hellenstrand KJ, Bexton RS, Nathan AW et al (1982) Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J 48:140–148

    Google Scholar 

  24. Pristowsky EN, Heger JJ, Chilson DA et al (1984) Antiarrhythmic and electrophysiologic effect of oral propafenone. Am J Cardiol 54:26D–28D

    Article  Google Scholar 

  25. Benaim R, Uzan C (1978) Les effects antiarythmiques de l’amiodarone injectable (à propos de 153 cas). Rev Med 19:1959–1963

    Google Scholar 

  26. Morady F, Scheinman MM, Shen E et al (1983) Intravenous amiodarone in the acute treatment of recurrent symptomatic ventricular tachycardia. Am J Cardiol 51:156–159

    Article  PubMed  CAS  Google Scholar 

  27. Galve E, Rius T, Ballester R et al (1996) Intravenous amiodarone in treatment of recent-onset atrial fibrillation:results of a randomized, controlled study. J Am Coll Cardiol 27:1079–1082

    Article  PubMed  CAS  Google Scholar 

  28. Vos MA, Golitsyn RS, Stangl K et al (1998) Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide-Sotalol Comparator Study Group. Heart 79:568–575

    PubMed  CAS  Google Scholar 

  29. Stambler BS, Wood MA, Ellenbogen KA et al (1996) Efficacy and safety of repeated doses of ibutilide for rapid conversion of atrial fibrillation and flutter. Ibutilide Repeat Dose Study Investigators. Circulation 94:1613–1621

    PubMed  CAS  Google Scholar 

  30. Deedwania PC, Singh BN, Ellenbogen K et al (1998) Spontaneos conversion and maintenance of sinus rhythm by amiodarone in patients with heart failure and atrial fibrillation: observations from the veterans affairs congestive heart failure survival trial of antiarrhythmic therapy (CHF-STAT). Circulation 98:2574–2579

    PubMed  CAS  Google Scholar 

  31. Falk RH, Pollak A, Singh SN et al (1997) Intravenous dofetilide, a class III antiarrhythmic agent, for termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol 29:385–390

    Article  PubMed  CAS  Google Scholar 

  32. Top-Pedersen, Moller M, Bloch-Thomsen PE et al (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish Investigations of Arrhythmias and Mortality on Dofetilide Study Group. N Engl J Med 341:857–865

    Article  Google Scholar 

  33. Klein AL, Grimm RA, Murray RD et al (2001) Use of trans-oesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 344:1411–1420

    Article  PubMed  CAS  Google Scholar 

  34. Norgaard BL, Wachtell K, Christensen PD et al (1999) Efficacy and safety of intravenously administered dofetilide in acute termination of atrial fibrillation and flutter: a multicenter, randomized, double-blind, placebo-controlled trial. Danish Dofetilide in Atrial Fibrillation and Flutter Study Group. Am Heart J 137:1062–1069

    Article  PubMed  CAS  Google Scholar 

  35. Lindeboon JE, Kingma JH, Crjins HJ et al (2000) Efficacy and safety of intravenous dofetilide for rapid termination of atrial fibrillation and atial flutter. Am J Cardiol 85:1031–1033

    Article  Google Scholar 

  36. Horowitz LN, Spielman SR, Greenspan AM et al (1985) Use of amiodarone in the treatment of persitent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 6:1402–1407

    Article  PubMed  CAS  Google Scholar 

  37. Blevius RD, Kerin NZ, Benaderet D et al (1987) Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 147:1401–1404

    Article  Google Scholar 

  38. Gosselink ATM, Crijns HJ, Van Gelder IC et al (1992) Low-dose amiodarone for maintenance of sinus rhythm after cadioversion of atrial fibrillation or flutter. JAMA 267:3289–3293

    Article  PubMed  CAS  Google Scholar 

  39. Singh S, Zoble RG, Yellen L et al (2000) Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) Study. Circulation 102:2385–2390

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dipartimento di Cardiologia, Ospedale SS. Annunziata, Taranto, Italy

    N. Baldi, V. A. Russo, L. Di Gregorio, V. Morrone, L. Liconso & G. Polimeni

Authors
  1. N. Baldi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. A. Russo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. L. Di Gregorio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Morrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L. Liconso
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G. Polimeni
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Divisione di Cardiologia, Ospedale Umberto I, Via Circonvallazione 50, I-30174, Venezia Mestre

    Antonio Raviele MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Italia

About this chapter

Cite this chapter

Baldi, N., Russo, V.A., Di Gregorio, L., Morrone, V., Liconso, L., Polimeni, G. (2006). Pharmacological Cardioversion of Atrial Fibrillation: Which Drugs Are Preferred, Class IC or Class III?. In: Raviele, A. (eds) Cardiac Arrhythmias 2005. Springer, Milano. https://doi.org/10.1007/88-470-0371-7_12

Download citation

  • DOI: https://doi.org/10.1007/88-470-0371-7_12

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0370-5

  • Online ISBN: 978-88-470-0371-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation